PCVX – Vaxcyte Inc.
Vaxcyte, Inc.PCVX
$46.88Name : Vaxcyte, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,769,363,456.00
EPSttm : -6.89
Vaxcyte, Inc.
$46.88
1.19%$0.55
PCVX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.77
Margin Of Safety %
Put/Call OI Ratio
2.4
EPS Next Q Diff
0.14
EPS Last/This Y
-2.85
EPS This/Next Y
1.06
Price
46.84
Target Price
109
Analyst Recom
1.2
Performance Q
-19.51
Upside
-620.4%
Beta
1.26
Ticker: PCVX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | PCVX | 53.97 | 2.15 | 1.99 | 60835 |
| 2026-05-12 | PCVX | 54.06 | 2.20 | 2.81 | 69873 |
| 2026-05-13 | PCVX | 54.25 | 2.26 | 122.06 | 79893 |
| 2026-05-14 | PCVX | 53.55 | 2.36 | 2.83 | 84744 |
| 2026-05-15 | PCVX | 52.39 | 2.36 | 0.08 | 84664 |
| 2026-05-18 | PCVX | 48.43 | 2.21 | 0.08 | 80208 |
| 2026-05-19 | PCVX | 48.83 | 2.19 | 111.33 | 80499 |
| 2026-05-20 | PCVX | 47.17 | 2.18 | 24.22 | 80463 |
| 2026-05-21 | PCVX | 47.41 | 2.22 | 20.63 | 81411 |
| 2026-05-22 | PCVX | 47.32 | 2.24 | 3.33 | 81898 |
| 2026-05-26 | PCVX | 50.11 | 2.24 | 0.00 | 81903 |
| 2026-05-27 | PCVX | 51.03 | 2.23 | 3820.00 | 81955 |
| 2026-05-28 | PCVX | 51.03 | 2.33 | 71.00 | 84335 |
| 2026-05-29 | PCVX | 51.43 | 2.37 | 0.12 | 85380 |
| 2026-06-02 | PCVX | 47.41 | 2.43 | 0.02 | 84757 |
| 2026-06-03 | PCVX | 46.95 | 2.43 | 2.80 | 84763 |
| 2026-06-04 | PCVX | 48.73 | 2.43 | 0.03 | 84777 |
| 2026-06-05 | PCVX | 47.37 | 2.41 | 0.01 | 85010 |
| 2026-06-08 | PCVX | 46.33 | 2.40 | 3.33 | 85123 |
| 2026-06-09 | PCVX | 46.85 | 2.40 | 4.38 | 85124 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | PCVX | 54.01 | -54.5 | - | -7.77 |
| 2026-05-12 | PCVX | 54.06 | -71.9 | - | -8.48 |
| 2026-05-13 | PCVX | 54.30 | -71.9 | - | -8.48 |
| 2026-05-14 | PCVX | 53.53 | -71.9 | - | -8.48 |
| 2026-05-15 | PCVX | 52.39 | -71.9 | - | -8.48 |
| 2026-05-18 | PCVX | 48.41 | -71.9 | - | -8.48 |
| 2026-05-19 | PCVX | 48.84 | -71.9 | - | -8.48 |
| 2026-05-20 | PCVX | 47.18 | -71.9 | - | -8.48 |
| 2026-05-21 | PCVX | 47.40 | -71.9 | - | -8.48 |
| 2026-05-22 | PCVX | 47.32 | -71.9 | - | -8.48 |
| 2026-05-26 | PCVX | 50.09 | -71.9 | - | -8.48 |
| 2026-05-27 | PCVX | 51.01 | -71.9 | - | -8.48 |
| 2026-05-28 | PCVX | 51.06 | -71.9 | - | -8.48 |
| 2026-05-29 | PCVX | 51.42 | -71.9 | - | -8.48 |
| 2026-06-01 | PCVX | 48.88 | -71.9 | - | -8.48 |
| 2026-06-02 | PCVX | 47.40 | -71.9 | - | -8.48 |
| 2026-06-03 | PCVX | 46.93 | -71.9 | - | -8.48 |
| 2026-06-04 | PCVX | 48.72 | -71.9 | - | -8.48 |
| 2026-06-05 | PCVX | 47.36 | -71.9 | - | -8.48 |
| 2026-06-08 | PCVX | 46.31 | -71.9 | - | -8.48 |
| 2026-06-09 | PCVX | 46.84 | -71.9 | - | -8.48 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | PCVX | -1.12 | 6.68 | 10.20 |
| 2026-05-12 | PCVX | -1.12 | 6.68 | 10.05 |
| 2026-05-13 | PCVX | -1.12 | 6.68 | 10.05 |
| 2026-05-14 | PCVX | -1.12 | 6.68 | 10.05 |
| 2026-05-15 | PCVX | -1.12 | 6.68 | 10.05 |
| 2026-05-18 | PCVX | -1.12 | 6.75 | 10.04 |
| 2026-05-19 | PCVX | -1.12 | 6.75 | 10.04 |
| 2026-05-20 | PCVX | -1.12 | 6.75 | 10.04 |
| 2026-05-21 | PCVX | -1.12 | 6.75 | 10.04 |
| 2026-05-22 | PCVX | -1.12 | 6.75 | 10.04 |
| 2026-05-26 | PCVX | -1.12 | 12.03 | 10.02 |
| 2026-05-27 | PCVX | -1.24 | 12.03 | 10.02 |
| 2026-05-28 | PCVX | -1.24 | 12.03 | 9.77 |
| 2026-05-29 | PCVX | -1.24 | 12.03 | 9.77 |
| 2026-06-02 | PCVX | -1.24 | 11.25 | 9.77 |
| 2026-06-03 | PCVX | -1.24 | 11.25 | 9.77 |
| 2026-06-04 | PCVX | -1.31 | 11.25 | 9.77 |
| 2026-06-05 | PCVX | -1.31 | 11.25 | 9.77 |
| 2026-06-08 | PCVX | -1.31 | 11.29 | 9.77 |
| 2026-06-09 | PCVX | -1.31 | 11.29 | 9.77 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-2.3
Avg. EPS Est. Current Quarter
-2.1
Avg. EPS Est. Next Quarter
-2.16
Insider Transactions
-1.31
Institutional Transactions
11.29
Beta
1.26
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
8
Growth Score
19
Sentiment Score
50
Actual DrawDown %
61.3
Max Drawdown 5-Year %
-76.2
Target Price
109
P/E
Forward P/E
PEG
P/S
P/B
2.26
P/Free Cash Flow
EPS
-6.97
Average EPS Est. Cur. Y
-8.48
EPS Next Y. (Est.)
-7.42
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.94
Return on Equity vs Sector %
-59.1
Return on Equity vs Industry %
-42.9
EPS 1 7Days Diff
-1.1
EPS 1 30Days Diff
-1.09
EBIT Estimation
◆
PCVX
Healthcare
$46.88
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37.3
Range 1M
13%
Sup Dist
3.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-44.5%
EPS NY
18%
52W%
49.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+132.5% upside
Upside
+132.5%
Quality
8
Vaxcyte, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 507
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX
Latest News
—
Caricamento notizie per PCVX…
stock quote shares PCVX – Vaxcyte Inc. Stock Price stock today
news today PCVX – Vaxcyte Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PCVX – Vaxcyte Inc. yahoo finance google finance
stock history PCVX – Vaxcyte Inc. invest stock market
stock prices PCVX premarket after hours
ticker PCVX fair value insiders trading